OncoMatch/Clinical Trials/NCT07137793
Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
Is NCT07137793 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pentoxifylline 400mg plus chemotherapy for doxorubicin induced cardiotoxicity.
Treatment: Pentoxifylline 400mg plus chemotherapy — The goal of this clinical trial is to evaluate the cardioprotective effect of pentoxifylline against doxorubicin-induced cardiotoxicity in breast cancer patients. The main questions it aims to answer are: 1. What is the change in ejection fraction (primary outcome) in breast cancer patients receiving pentoxifylline compared to those who do not? 2. What are the changes in serum levels of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), and TNF-α (secondary outcomes) in breast cancer patients receiving pentoxifylline compared to those who do not? Researcher will compare breast cancer patients receiving standard chemotherapy alone (Group one: Positive control group; n=23) to breast cancer patients receiving standard chemotherapy plus pentoxifylline (Group two: pentoxifylline group; n=23) to see if pentoxifylline mitigates the cardiac side effects associated with doxorubicin treatment. Participants will: Be randomized to receive either a chemotherapeutic regimen alone or with pentoxifylline.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage I, II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: doxorubicin (doxorubicin)
Formerly treated with DOX.
Lab requirements
Blood counts
absolute neutrophilic count ≥ 1.5 ×10^9/L, platelet count ≥ 90 × 10^9/L and hemoglobin level ≥ 10 g/dl
Kidney function
Creatine Clearance ≥ 50 mL/min
Liver function
adequate liver function
Cardiac function
Echocardiographic LVEF ≥55%. History of heart failure or LVEF <50% [excluded]. Presence of any cardiac-related conditions such as angina pectoris, valvular disease, uncontrolled systemic hypertension, coronary heart disease, and cardiac surgery within the last 3 months [excluded].
Echocardiographic LVEF ≥55%. Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 ×10^9/L, platelet count ≥ 90 × 10^9/L and hemoglobin level ≥ 10 g/dl). Patients with adequate liver function and adequate renal function. Creatine Clearance < 50 mL/min [excluded]. History of heart failure or LVEF <50%. Presence of any cardiac-related conditions such as angina pectoris, valvular disease, uncontrolled systemic hypertension, coronary heart disease, and cardiac surgery within the last 3 months.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify